Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing in Patients With Minor Stroke or High Risk TIA (CYP2C19 and Stroke)
University of Alabama at Birmingham
Summary
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.
Description
This is a pilot clinical trial for feasibility
Eligibility
- Age range
- 18–89 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients 18-89 years of age * admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA * eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well) Exclusion Criteria: * diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability (subset of other determined etiology) or large vessel disease (culprit vessel stenosis of ≥50%) * prescribed anticoagulation prior to stroke * treated with intravenous thrombolys…
Interventions
- GeneticCYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
CYP2C19 is a gene that encodes an enzyme responsible for metabolizing several medications, including the antiplatelet drugs.
Location
- University of Alabama at BirminghamBirmingham, Alabama